Britannia Life Sciences Inc.
BLSIF
$0.04
$0.000.00%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.45M | 1.54M | 1.53M | 2.81M | 2.90M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.45M | 1.54M | 1.53M | 2.81M | 2.90M |
| Cost of Revenue | 673.70K | 678.00K | 617.20K | 617.20K | 542.90K |
| Gross Profit | 771.90K | 858.40K | 910.20K | 910.20K | 1.07M |
| SG&A Expenses | 1.64M | 1.37M | 1.41M | 1.41M | 1.42M |
| Depreciation & Amortization | 22.80K | 22.30K | 21.70K | 21.70K | 21.70K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.34M | 2.07M | 2.04M | 3.08M | 3.03M |
| Operating Income | -890.70K | -534.80K | -516.60K | -272.50K | -126.00K |
| Income Before Tax | -822.10K | -1.57M | -1.74M | -1.74M | -1.44M |
| Income Tax Expenses | 43.60K | 43.60K | 43.60K | 43.60K | 36.60K |
| Earnings from Continuing Operations | -0.87 | -1.62 | -1.78 | -1.78 | -1.47 |
| Earnings from Discontinued Operations | -- | 256.00K | 432.10K | 432.10K | 432.10K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -30.10K | -112.40K | -161.70K | -161.70K | 20.10K |
| Net Income | -895.80K | -1.47M | -1.51M | -5.90M | -5.40M |
| EBIT | -890.70K | -534.80K | -516.60K | -272.50K | -126.00K |
| EBITDA | -848.70K | -493.20K | -475.60K | -227.70K | -50.50K |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.04 | -0.03 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.04 | -0.03 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 649.02M | 649.02M | 649.02M | 649.02M | 649.02M |
| Average Diluted Shares Outstanding | 649.02M | 649.02M | 649.02M | 649.02M | 649.02M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |